WINNIPEG, Jan. 8 /CNW/ - (TSX: IM) -- IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") today announced that it has gained regulatory approval from the Korea Food & Drug Administration permitting the Company to immediately begin marketing its 1.5 Tesla and 3.0 Tesla IMRISneuro systems in South Korea.
"South Korea is one of the fastest growing medical equipment markets in the world," said David Graves, CEO of IMRIS. "We continue to expand our global presence, and receiving regulatory approval in South Korea is another important step in our continuing efforts to increase penetration of global markets with our products."
IMRISneuro has become the surgical imaging solution of choice by neurosurgeons around the world. No other system offers the same degree of safety for both the patient and the surgical environment. IMRISneuro does not require the patient to be transported for magnetic resonance scanning, so the optimum position for neurosurgery is never compromised. Clinical workflow and surgical access to the patient is not impacted and the magnet is removed completely from the operating room when scanning is complete. IMRISneuro provides neurosurgeons with timely images during surgery from which they are able to make better decisions for their patients.
IMRIS (TSX: IM) is a global leader in providing image guided therapy solutions. These solutions feature fully integrated surgical and interventional suites that incorporate magnetic resonance, fluoroscopy and computed tomography to deliver on demand imaging during procedures. The Company's systems serve the neurosurgical, cardiovascular and neurovascular markets and have been selected by leading medical institutions around the world.
SOURCE IMRIS Inc.
For further information: For further information: Brad Woods, Director Investor Relations & Corporate Communications, IMRIS Inc., Tel: (204) 480-7094, Email: firstname.lastname@example.org